X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Merck: Not the way to go forward - Outside View
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Merck: Not the way to go forward
May 3, 2010

It is not difficult to see why Merck Ltd - a 52% subsidiary of Merck KGaA of Germany - is not on top of the mind recall, in the pantheon of pharma stocks. For that matter it does not even feature in the investment options of the high strung investment broking fraternity. And it is because of its apparent lack of trying to get around the Indian muddy waters. For whatever reason this 43 year old legal Indian entity represents a muddling has been. A turnover of Rs 5 bn and an after tax profit of Rs 650 m is its magic mantra for the 12 month period ended Dec 2009. It may be pertinent to note that some 45% of its pretax profit of Rs 970 m comprises "other income" - largely made of of interest income on fixed deposits and dividend income from investments in securities.

Not having many clear ideas on how to go forward perhaps, the company has chosen to plonk down some Rs 3.5 bn at year end either with banks or in securities. It does keep shuffling between the two portfolios, not quite sure which investment brings in better returns.

It is however currently implementing one bright idea though - a buyback of shares -a neat trick to increase the hold of the parent over its Indian operations using its accumulated cash surplus - a trend that may well accelerate in the years to come - unless it wises up to other more intellectual diversions. By this method you also gets to report a higher EPS. The other bright idea of flogging its cash surplus was to buy and sell securities during the year - but the effort appears to have been largely wasted.

The problem that MNC pharma companies face worldwide is that they cannot make and market generics as a matter of policy as they do not want to get into bush wars with other MNCs whose products they end up duplicating. They have to stick to pure brands from their own portfolio of products. And its portfolio of products is attracting the Govt big stick.

The management claims that its operations are affected due to the discriminatory application of price controls by the Govt on what it makes and sells especially the bulk drug Vitamin E .The directors' report makes for very sorrowful reading indeed - a diatribe against the many sinful policies of a malignant Govt for the last many years, which is stunting its growth. The net result is that there is no investment in plant and machinery.

For the present its small manufacturing plant based at Goa - and which is highly depreciated to boot-- is being flogged to max capacity - and it also takes recourse to earning some extra moolah through trading operations - and this apparently includes third party processing - trading operations ring in 25% of total revenue. But in the end this effort really does not add up to much in its overall top line. It is not easy to configure how much bottomline is brought in through trading operations but it is reasonable to infer that its contribution is significant.

It also has a pharma R&D unit in Mumbai but its contribution to the company's overall wellbeing is unclear.

The small wonder then is that it still has over 24,000 shareholders at 2009 year end - apparently joining hands with the management in a show of solidarity of sorts.

The only silver lining is that on paper it is an ideal bonus candidate - an equity base of just Rs 166 m topped up with reserves of Rs 4.5 bn. But with the current implementation of its buyback policy and its perceived state of mourning, that is indeed an impossibility.

Disclosure: Please note that I am a shareholder of this company

This column "Cool Hand Luke" is written by Luke Verghese. Luke has been a business journalist, financial analyst and knowledge management head with a professional experience of more than 20 years. An avid watcher of the stock market, he has written extensively on stock market trends. His articles have featured in Business Standard, Financial Express and Fortune India amongst others. He has also been the Deputy Editor, Fortune India and the Financial Editor of The Business and Political Observer.

Disclaimer:
The views mentioned above are of the author only. Data and charts, if used, in the article have been sourced from available information and have not been authenticated by any statutory authority. The author and Equitymaster do not claim it to be accurate nor accept any responsibility for the same. The views constitute only the opinions and do not constitute any guidelines or recommendation on any course of action to be followed by the reader. Please read the detailed Terms of Use of the web site.
Equitymaster Agora Research Private Limited

Equitymaster requests your view! Post a comment on "Merck: Not the way to go forward". Click here!

  

More Views on News

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

MERCK LTD SHARE PRICE


Feb 19, 2018 (Close)

TRACK MERCK LTD

  • Track your investment in MERCK LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MERCK LTD - MYLAN COMPARISON

COMPARE MERCK LTD WITH

MARKET STATS